How is the Viral And Non-Viral Vector Manufacturing Market Poised for Growth: Trends and Opportunities Through 2034
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
How has the viral and non-viral vector manufacturing market grown over the years?
The expansion of the market for manufacturing viral and non-viral vectors has been swift in the past few years. It is projected to rise from a worth of $8.67 billion in 2024 to $10.3 billion in 2025, experiencing a compound annual growth rate (CAGR) of 18.8%. The historic growth can be accredited to factors like the increasing occurrence of genetic disorders, progress made in biotechnology, increasing financial contribution in gene therapy research, the growing cognizance of personalized medicine, and regulatory reinforcement for the development of gene therapy.
What Is the forecasted market size and growth rate for the viral and non-viral vector manufacturing market?
Projected to witness tremendous growth in the upcoming years, the market for viral and non-viral vector manufacturing is expected to reach $22.06 billion in 2029, with a CAGR of 21.0%. Factors contributing to this growth in the forecasted period include the escalating demand for gene therapies, wider applications in treating rare diseases, an upsurge in investments for developing biomanufacturing infrastructure, and the growing incorporation of precision medicine. Prevailing trends that will shape the market during the forecast period include the creation of advanced viral vectors, the rising use of CRISPR or cas9 technology in vector production, concentration on scalable and economical manufacturing processes, increasing acceptance of non-viral vectors, as well as the enhancements in cell and gene therapy manufacturing technologies.
Get your viral and non-viral vector manufacturing market report here!
What are the major factors driving growth in the viral and non-viral vector manufacturing market?
The rise in genetic abnormalities is anticipated to boost the expansion of both viral and non-viral vector production arenas. Genetic abnormalities encompass situations that are solely or partially induced by an alternation in the standard DNA sequence. Viral vectors function by distributing therapeutic genes to specific cells, thereby substituting or supplementing the faulty genes responsible for genetic diseases. Non-viral vectors, on the other hand, are typically employed in ex vivo gene therapy techniques, which involve genetically altering cells externally before reinfusing them back into the patient’s body. As an example, in June 2022, the International Diabetes Federation, based in Belgium, reported that the global prevalence of diabetes had climbed to 10.5%. This report also indicated that, shockingly, over half (44.7%) of these cases are still unrecognised, and approximately 783 million adults, or one out of every eight people, are projected to be diagnosed with diabetes by 2045. As a result, the escalating presence of genetic diseases contributes to the growth of both the viral and non-viral vector production markets.
What key areas define the segmentation of the global viral and non-viral vector manufacturing Market?
The viral and non-viral vector manufacturing market covered in this report is segmented –
1) By Vector Type: Viral Vector, Non-Viral Vector
2) By Disease: Cancer, Genetic Disease, Infectious Disease, Cardiovascular Disease, Other Diseases
3) By Application: Gene Therapy, Vaccinology, Cell Therapy, Other Applications
Subsegments:
1) By Viral Vector: Adenoviral Vectors, Lentiviral Vectors, AAV (Adeno-Associated Virus) Vectors, Retroviral Vectors, Other Viral Vectors
2) By Non-Viral Vector: Plasmid DNA, Lipid-Based Vectors, Nanoparticles, Electroporation-Based Vectors, Other Non-Viral Vectors
Get your free sample now – explore exclusive market insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12570&type=smp
What are the top market players propelling the growth of the viral and non-viral vector manufacturing industry?
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
What are the key trends shaping the future of the viral and non-viral vector manufacturing market?
The rise in technological innovation is a significant trend being witnessed in the market of viral and non-viral vector manufacturing. Several leading firms are creating advanced solutions to maintain their standing in the market. An example of this is Merck KGaA, a company based in Germany that focuses on science and technology. In August 2022, they introduced the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform. This makes them one of the inaugural Contract development and manufacturing organizations also known as technology creators, to proffer a complete viral vector manufacturing kit comprising of AAV, Lentiviral, CDMO, CTO, and process development. This groundbreaking platform aids biopharmaceutical companies in reducing the cost and duration of process development while also hastening the journey to clinical manufacture.
Unlock exclusive market insights – purchase your research report now for a swift delivery!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12570
What regions are dominating the viral and non-viral vector manufacturing market growth?
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Browse Through More Similar Reports By The Business Research Company:
Viral Vectors And Plasmid DNA Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/viral-vectors-and-plasmid-dna-global-market-report
Antivirals Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antivirals-global-market-report
Antiviral Combination Therapy Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/antiviral-combination-therapy-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
